



NUMINUS
INTELLIGENCE

AI Enabling the New Paradigm for Mental Health Care

Numinus Wellness Inc.
(TSX: NUMI | OTCQX: NUMIF) +

MedBright AI Investments Inc.
(CSE: MBAI | OTCQB: MBAIF)



Lorem ipsum dolor sit amet,
consectetur adipiscing elit,
sed diam nonummy nibh
euismod tincidunt ut laoreet
dolore magna aliquam erat



Lorem ipsum dolor sit amet,
consectetur adipiscing elit,
sed diam nonummy nibh
euismod tincidunt ut laoreet
dolore magna aliquam erat

Disclaimer

This presentation of Numinus Wellness Inc. (the “**Company**” or “**Numinus**”) is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell, issue or subscribe for any securities in any jurisdiction, and under no circumstances is it to be construed as a prospectus or advertisement or public offering of the securities. This presentation is confidential and is being provided to you solely for your information and may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. Any forwarding, distribution or reproduction of this presentation, in whole or in part, is unauthorized. By accepting and reviewing this presentation, you acknowledge and agree (i) to maintain the confidentiality of this presentation and the information contained herein, (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care, and (iii) to not utilize any of the information contained herein except to assist with your evaluation of the Company.

Forward-Looking Statements

This presentation includes certain “forward-looking information” and “forward-looking statements” (collectively “**forward-looking statements**”) within the meaning of applicable Canadian securities legislation, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities, operating performance, financial performance and economic conditions. All statements in this presentation that address events or developments that the Company expects to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are often identified by words such as “expect”, “plan”, “anticipate”, “project”, “target”, “potential”, “schedule”, “forecast”, “budget”, “estimate”, “intend”, “on track” or “believe” and similar expressions or their negative connotations, or that events or conditions “will”, “would”, “may”, “could”, “should”, or “might” occur, and including information regarding: expectations that the Company will acquire MedBright AI Inc. (“**MedBright**”); expectations of the potential benefits of the acquisition of MedBright, including the combined company’s anticipated cash and liquid securities position, and the ability of the combined company to successfully achieve business objectives; expectations concerning anticipated revenues and profitability; estimates and expectations around the growth of the integrated mental health and ketamine-assisted therapy industries, related industries and the benefits and impact of this growth on the business and operations of Numinus; expectations regarding the future value of Spravato®; the anticipated benefits of MedBright’s AI technology in respect of the Company; the Company’s anticipated annual capacity to instruct practitioners; the anticipated opportunity for the Company to add new drugs and modalities to its AI platform; expectations as to the number of patients in the US market with diagnoses that are appropriate for reimbursement; and expectations related to other economic, business, and/or competitive factors.

Forward-looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond the Company’s control. These forward-looking statements are qualified in their entirety by the following factors: the proposed transaction with MedBright may not close on the timeline anticipated or at all; the potential benefits of the acquisition of MedBright and its AI technology in respect of the Company may not be as anticipated; the anticipated revenues and profitability of the combined Company may not be as anticipated; the integrated mental health and ketamine-assisted therapy industries may not grow as expected, and such growth may not benefit the Company’s business and operations; the future value of Spravato® may not be as anticipated; the Company’s annual capacity to instruct practitioners may be less than forecasted; the number of patients in the US market with diagnoses that are appropriate for reimbursement may be fewer than anticipated; as well the cautionary statements and risk factor disclosure contained in filings made by the Company with the Canadian securities regulators, including the Company’s financial statements and related MD&A for the three and six months ended February 29, 2024, all filed with the securities regulatory authorities in all provinces and territories of Canada, except Quebec, and available under the Company’s profile at www.sedarplus.ca. These risk factors are not exhaustive of the factors that may affect the Company’s forward-looking statements.

The Company’s forward-looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management of the Company at such time. The Company does not assume any obligation to update forward-looking statements if circumstances or management’s beliefs, expectations, or opinions should change other than as required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, undue reliance should not be placed on forward-looking statements. The Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.

Numinus Wellness to Acquire MedBright AI

Relaunch as Numinus Intelligence:
AI-enabling mental health clinics across the US

SAME MISSION:

Address the US mental health crisis by ensuring access to reimbursed traditional and psychedelic-assisted therapy.

SIGNIFICANT NEW AI OPPORTUNITY:

Leveraging 7 years of deep data and vast knowledge into an AI technology focused plan to drive revenue by expanding drug-assisted therapy to every patient in need.

SOLID BALANCE SHEET, IMPROVING CASH FLOW


Cash and liquid securities in excess of \$5M as part of the combination
Cost reductions and revenue improvement plan underway

Ketamine-assisted therapy (KAT) rapidly growing into a mainstream mental health treatment

- **US\$6.9 billion** revenue by 2030¹
- **CAGR of 10.6%** from '23 to '30
- Driven by **rising rates** of PTSD, depression and anxiety, with **1 in 5** American adults experiencing mental health issues²
- **Numinus** clinics are one of the **largest billers** for ketamine therapy reimbursement
 - Captured data from 237,000 reimbursed claims
 - Processed over 200,000 inbound calls into its patient enrollment call center
 - 48,000 patients in its EHR system

Spravato® Worldwide Sales³

(US\$ millions)




1. U.S. Ketamine Clinics Market Size & Share Report, 2030, Grandview Research
 2. National Alliance on Mental Health
 3. Johnson & Johnson, Q4 2023 earnings report, Jan. 23, 2024
 4. Johnson & Johnson, Enterprise Business Review, Dec. 5, 2023

Services for mental health are in demand, but therapists are challenged to provide reimbursed care for drug-assisted therapy

To generate reimbursed revenue a single therapist needs infrastructure:

- A call center to convert patients to new appointments
- Pre-authorization system to ensure insurance coverage
- Drug delivery protocols
- Clinical notes to bill
- Billing process for relevant reimbursement codes
- After-care process and recurring therapy protocols and reimbursement

All of these services can be delivered through the development of a MedBright AI-bot, simplifying the process and reducing costs



The Numinus journey to creating the next generation of mental health infrastructure

- **Setting the gold standard** in psychiatric services, medicine management, psychotherapy, and advanced therapies like Ketamine-assisted therapy and Transcranial Magnetic Stimulation.
- **Strategic relationships** in place with leading psychedelic drug developers such as Lykos, Compass Pathways, Usona, MindMed, and Beckley
- Positioned at the **forefront of late-phase clinical trials** for MDMA, Psilocybin, LSD, and 5-MeO-DMT
- **Clinical research** unit has conducted **40 trials** over **2 years**
- **Practitioner training program** with capacity to instruct **over 1,000 learners** per year and a research training program for drug sponsors

Infrastructure and data collected provide the platform to reshape the business model into a scalable AI offering designed to generate a revenue stream with massive operational leverage:

- 23,000+ patients over 4 years and 48,000+ patient charts in its EHR
- Billing center that has billed and collected USD\$35.4M in claims over 4 years
- 237,000+ reimbursed claims
- Call center with 120,000 inbound calls per year
- 5 clinics in current operation administering over 65,000 appointments annually

Quickly bringing Spravato[®] online as a reimbursable therapy

CHALLENGE:

- Launching a newly approved medicine required building capabilities throughout Numinus' entire operation
- Extensive training was required for prescribers, therapists and staff
- Numinus needed to understand and comply with regulatory procedures and requirements such as the FDA's Risk Evaluation and Mitigation Strategy (REMS) program
- To ensure optimal client access, insurance payors needed to be negotiated with and set up

ACTION TAKEN:


- Creating suitable rooms and treatment spaces
- Training therapists and prescribers
- Building and maintaining compliance with the FDA's REMS program
- Securing and setting up insurance payors, including billing code set-up and maximizing prior authorizations
- Creating clinic operating procedures and policies and training management and staff
- Setting up Electronic Medical Records
- Generating awareness through engagement with the medical community

RESULTS:

- **Numinus was the first clinic in the US to be Spravato[®] ready prior to FDA approval**
- Today, over 7,500 Spravato[®] and 5,000 ketamine sessions are administered annually through Numinus clinics, of which 80% are payor-reimbursed
- Numinus remains a top provider in the US and is considered an “expert provider” by Janssen, given the large clinical data set and collection of outcomes in real-time clients through engagement with the medical community

A scalable platform designed to easily add newly approved compounds and therapies

- Ketamine therapy support
- As approved, **new drugs** and modalities **easily added** to AI platform
- **Revenue upside** with additional AI modules introduced to installed base



Numinus' deep data and vast knowledge can drive a scalable revenue stream with significant operational leverage

Developing an AI-enabled solution for the US market of over 200,000 mental health providers:

- 67,000 psychiatry providers
- 106,000 clinical therapists
- 50,000 family and marriage therapists

Enabling a transition from low-margin reimbursed talk therapy to high-margin psychedelic-assisted therapy to meet growing patient demand

PROBLEM


Patients and providers have significant costs and challenges securing mental health payments for services in the US from health insurance companies

SOLUTION

Provide an AI-bot to generate the necessary documentation and support to reduce costs and increase access

A trained model can access deep data on accepted and rejected claims and learn how to build an AI-bot that can provide data quickly and accurately to ensure full coverage seamlessly

MedBright AI focuses on the intersection of healthcare and technology to create clinical efficiency and improve profit



MedBright AI History, listed on the CSE:MBAI

MBAI News Releases

November 22, 2023 - MedBright AI Investments and The Ken Sperling Lecture Series Support Medical Economics Lectures at Yale University Medical School

December 7, 2023 - MedBright AI Announces Beta Customer for MedMatrix, the AI-Driven Data and Analytics Platform

January 23, 2024 - MedBright AI's MedMatrix to Expand Its AI Offerings for Cosmetic Marketing & Clinical Trial Analytics

February 27, 2024 - MedMatrix Product Moves from Beta to Full Commercialization, Announces AI Product Suite

March 20, 2024 - Rejuvenation Medical Group of Canada uses MedMatrix AI Reporter to Streamline Reporting and Improve Operations

May 2, 2024 - MedBright AI Announces New Commercial Product Demos for MedMatrix AI Platform

Financial opportunity

- Numinus clinics currently generate reimbursed revenue from **46 health practitioners** and an average of **5,250 appointments** per month.
- Target Market: **200,000+**¹ therapists in the US
- Estimated **14 million**¹ patients with diagnoses that are appropriate for reimbursement

1. Management estimates

